» Articles » PMID: 25288119

The Nature of Embryonic Stem Cells

Overview
Publisher Annual Reviews
Specialty Cell Biology
Date 2014 Oct 8
PMID 25288119
Citations 205
Authors
Affiliations
Soon will be listed here.
Abstract

Mouse embryonic stem (ES) cells perpetuate in vitro the broad developmental potential of naïve founder cells in the preimplantation embryo. ES cells self-renew relentlessly in culture but can reenter embryonic development seamlessly, differentiating on schedule to form all elements of the fetus. Here we review the properties of these remarkable cells. Arising from the stability, homogeneity, and equipotency of ES cells, we consider the concept of a pluripotent ground state. We evaluate the authenticity of ES cells in relation to cells in the embryo and examine their utility for dissecting mechanisms that confer pluripotency and that execute fate choice. We summarize current knowledge of the transcription factor circuitry that governs the ES cell state and discuss the opportunity to expose molecular logic further through iterative computational modeling and experimentation. Finally, we present a perspective on unresolved questions, including the challenge of deriving ground state pluripotent stem cells from non-rodent species.

Citing Articles

Chlorogenic acid promotes fatty acid beta-oxidation to increase hESCs proliferation and lipid synthesis.

Zong M, Ji J, Wang Q, Cai Y, Chen L, Zhang L Sci Rep. 2025; 15(1):7095.

PMID: 40016322 PMC: 11868603. DOI: 10.1038/s41598-025-91582-z.


A CRISPR/Cas9-based kinome screen identifies ErbB signaling as a new regulator of human naïve pluripotency and totipotency.

Li J, Lin X, Xie L, Zhao J, Han C, Deng H Life Med. 2025; 2(4):lnad037.

PMID: 39872545 PMC: 11749542. DOI: 10.1093/lifemedi/lnad037.


Scalable control of stem cell fate by riboswitch-regulated RNA viral vector without genomic integration.

Kim N, Yokobayashi Y Mol Ther. 2025; 33(3):1213-1225.

PMID: 39797398 PMC: 11897756. DOI: 10.1016/j.ymthe.2025.01.005.


Stem cells researches and therapies towards endocrine diseases treatment; strategies, challenges, and opportunities.

Sarvari M, Alavi-Moghadam S, Aghayan H, Tayanloo-Beik A, Payab M, Tootee A J Diabetes Metab Disord. 2024; 23(2):1461-1467.

PMID: 39610510 PMC: 11599503. DOI: 10.1007/s40200-020-00674-2.


A suboptimal OCT4-SOX2 binding site facilitates the naïve-state specific function of a Klf4 enhancer.

Waite J, Boytz R, Traeger A, Lind T, Lumbao-Conradson K, Torigoe S PLoS One. 2024; 19(9):e0311120.

PMID: 39348365 PMC: 11441684. DOI: 10.1371/journal.pone.0311120.